Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
NEUROCRINE BIOSCIENCES INC (NBIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Other Events  Interactive Data
10/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints"
08/01/2023 8-K Quarterly results
07/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BYLAW AMENDMENT"
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/03/2023 8-K Quarterly results
02/10/2023 8-K Quarterly results
02/06/2023 8-K Quarterly results
Docs: "Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023"
01/09/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases - Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following Phase 1 readout -"
11/01/2022 8-K Quarterly results
08/30/2022 8-K Regulation FD Disclosure  Interactive Data
08/04/2022 8-K Quarterly results
Docs: "Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance"
05/31/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
02/11/2022 8-K Quarterly results
Docs: "Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022"
01/06/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones"
12/23/2021 8-K Other Events  Interactive Data
11/22/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders"
11/01/2021 8-K Quarterly results
Docs: "Neurocrine Biosciences Reports Third Quarter 2021 Financial Results"
08/03/2021 8-K Quarterly results
Docs: "Neurocrine Biosciences Reports Second Quarter 2021 Financial Results"
05/21/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
11/24/2020 8-K Other Events  Interactive Data
11/19/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Neurocrine Biosciences Announces Repurchase of Convertible Notes"
11/09/2020 8-K Quarterly results
Docs: "Neurocrine Biosciences Reports Third Quarter 2020 Financial Results"
09/10/2020 8-K Investor presentation
Docs: "the 15th Annual Citi Biopharma Conference. I'm Neena Birtritto-Garg."
08/28/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy